Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 and 50mg in Asia Pacific Adults With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 393 participants.
Also called NCT01647542
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 393 participants
- Sponsor
- Registry
-
NCT01647542 -
U1111-1129-7865
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Australia, China, New Zealand, South Korea, Taiwan
- Registry status
- Terminated
Technical summary
Registry record NCT01647542. Randomized; quadruple masking; primary purpose treatment. Start 2012-10 (registry gives no type); primary completion 2014-02 (actual). Results posted on 2015-08-19.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 and 50mg in Asia Pacific Adults With Type 2 Diabetes
- Acronym
- GRAND-307
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- TAK-875
- Intervention (Drug)
- TAK-875 Placebo
- Lead sponsor
- Takeda
Record details
- Record id
cardio:ct-nct01647542- Content hash
9409571a3004a7c22b1de8c37efdda66004577dbd9683c43f494ab262f30570f